Business
Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin
This Fourth Patent for AR101/Enzastaurin Strengthens and Broadens the Intellectual Property Portfolio Surrounding the Treatment of Inherited Vascular
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"This Fourth Patent for AR101/Enzastaurin Strengthens and Broadens the Intellectual Property Portfolio Surrounding the Treatment of Inherited Vascular Disorders Including Vascular Ehlers-Danlos Syndrome (VEDS).Multiple Patent Families Filed in Key Global MarketsENGLEWOOD, CO / ACCESSWIRE / September 14, 2022 / Aytu BioPharma, Inc. (the Company or \"Aytu\") (Nasdaq:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, today announced the addition of a fourth patent to the intellectual property suite surrounding AR101/Enzastaurin. This fourth patent, also licensed from Johns Hopkins University, is titled \"Pathway Targets for the Treatment of Vascular Ehlers-Danlos Syndrome,\" expands the scientific evidence of the pathophysiology of Vascular Ehlers-Danlos Syndrome (VEDS) and is highly confirmatory of the therapeutic approach for AR101/Enzastaurin. The patent has an expiry date of September 2041, assuming no patent term extensions.\"We're excited about the continued evidence being generated in support of AR101/Enzastaurin for the treatment of VEDS,\" remarked Josh Disbrow, Chief Executive Officer of Aytu BioPharma. \"Adding this fourth patent to the portfolio deepens and broadens the intellectual property surrounding AR101/Enzastaurin for the treatment of inherited vascular disorders, including VEDS, for which we are advancing AR101 as an initial indication. We expect to advance the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023.\"About Vascular Ehlers-Danlos Syndrome (VEDS)Vascular Ehlers-Danlos Syndrome is the severe subtype of Ehlers-Danlos Syndrome, affecting 1 in 50,000 people worldwide and results from pathogenic variants in the COL3A1 gene, which encodes the chains of type III procollagen, a major protein in vessel walls and hollow organs. Twenty-five percent of VEDS patients have a first complication by the age of 20 years, and more than eighty percent have at least one complication by the age of 40. VEDS is a devastating condition, and VEDS patients have a median lifespan of 51 years. There are currently no approved therapies for VEDS.About AR101 (enzastaurin)AR101 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the...